ArticleJournal of veterinary internal medicine2026
Adverse events in small dogs treated with a single dose of vinblastine.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVinblastine (VBL) is a chemotherapeutic agent commonly used to treat malignant tumors in dogs. Although a maximum tolerated dose of 3.5 mg/m2 has been reported, the safety and tolerability of this dose in small dogs remain inadequately characterized. HYPOTHESIS/
objectivesRetrospectively evaluate adverse events (AEs) associated with a single IV administration of VBL at a dosage of 2.0 mg/m2 in dogs weighing < 10 kg. We hypothesized that AE occurrences in small dogs would be comparable to those reported in phase I studies involving larger breeds. ANIMALS: Forty client-owned dogs weighing < 10 kg with malignant tumors.
methodsAdverse events after a single IV VBL administration at a dosage of 2.0 mg/m2 were retrospectively evaluated in small dogs with malignant tumors. Myelosuppressive and gastrointestinal AEs were graded using VCOG-CTCAE v2.0 criteria.
resultsNeutropenia and thrombocytopenia were observed in 82.5% (33/40) and 5.0% (2/40) of dogs, respectively. Grade 3 or 4 neutropenia occurred in 32.5% (13/40), comprising 15.0% (6/40) with Grade 3 and 17.5% (7/40) with Grade 4 events. Inappetence, vomiting, and diarrhea were reported in 7.5% (3/40), 7.5% (3/40), and 25.0% (10/40) of dogs, respectively, and were generally mild. Febrile neutropenia was noted in 5.0% (2/40) of dogs. CONCLUSIONS AND CLINICAL IMPORTANCE: Vinblastine administered at a dosage of 2.0 mg/m2 in small dogs with malignant tumors resulted in gastrointestinal toxicity within clinically acceptable limits, but close monitoring for neutropenia is warranted. These findings suggest that dose escalation of VBL, as reported in larger dogs, may not be feasible in smaller dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.